Angiogenic Biomarkers in Juvenile Idiopathic Arthritis

NCT05534347 | Recruiting

• 2 other identifiers: APHP2203642022-A00468-35
• Study Type: observational
• Target: 300
• Locations: 1 country
• Sites: 1

Brief Summary

The aim of the study is to determine whether serum inflammatory angiogenic markers (eg, semaphorins, CCN1) predict severity of juvenile idiopathic arthritis defined by structural progression and/or therapeutic escalation.

Conditions

Juvenile Idiopathic Arthritis (JIA)

Keywords

Juvenile idiopathic arthritis (JIA); JIA patients in transition towards adult ward; Prognosis of JIA; Severity and structural damage in JIA; Angiogenic and inflammatory biomarkers; Semaphorin (SEMA4A), CCN1; Serum fluid; Synovial fluid

Outcome Measures

Primary Outcomes (4)

• Dosage of angiogenic markers

  Dosage of angiogenic markers by ELISA method in serum. Determine if angiogenic and inflammatory biomarkers are predictive of a more severe disease as reflected by structural joint damage and treatments received. Activity measured with questionnaires, and treatments received. Structural damage determined by x-rays during follow up.

  5 years

• Dosage of angiogenic markers

  Dosage of angiogenic markers by ELISA method in synovial fluid if available. Determine if angiogenic and inflammatory biomarkers are predictive of a more severe disease as reflected by structural joint damage and treatments received. Activity measured with questionnaires, and treatments received. Structural damage determined by x-rays during follow up.

  5 years

• Dosage of inflammatory markers by ELISA method

  Dosage of inflammatory markers by ELISA method in serum. Determine if angiogenic and inflammatory biomarkers are predictive of a more severe disease as reflected by structural joint damage and treatments received. Activity measured with questionnaires, and treatments received. Structural damage determined by x-rays during follow up.

  5 years

• Dosage of inflammatory markers by ELISA method

  Dosage of inflammatory markers by ELISA method in synovial fluid if available. Determine if angiogenic and inflammatory biomarkers are predictive of a more severe disease as reflected by structural joint damage and treatments received. Activity measured with questionnaires, and treatments received. Structural damage determined by x-rays during follow up.

  5 years

Secondary Outcomes (5)

• Questionnaires

  5 years

• Collection of treatments received

  5 years

• Structural damage determined by x-rays

  5 years

• Angiogenic biomarkers

  At inclusion

• Inflammatory biomarkers

  At inclusion

Study Arms (1)

Juvenile Idiopathic Arthritis

Patients seen in a specialized rheumatology consultation for the management of juvenile idiopathic arthritis in an adult service, after information and collection of their non-opposition.

Biological: Blood sample; Biological: Joint puncture

Interventions

Blood sample BIOLOGICAL

Addtional tube of blood needed for follow up of patients

Juvenile Idiopathic Arthritis

Joint puncture BIOLOGICAL

Joint puncture if needed according to routine care of the patients

Juvenile Idiopathic Arthritis

Eligibility Criteria

• Age: 16 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Patients over (or egal) 16 years old with diagnosis of Juvenile Idiopathic Arthritis starting their follow up in adult rheumatology ward in Cochin hospital

You may qualify if:

• Greater than or equal to 16 years-old
• Diagnosis of Juvenile Idiopathic Arthritis with specialized follow up in Rheumatology at Cochin Hospital
• No-opposition to the research
• Patient with health insurance
• Mastery of the French language

You may not qualify if:

• Patient under curatorship or guardianship
• Patient receiving french state medical aid

Sponsors & Collaborators

• Assistance Publique - Hôpitaux de Paris: lead
• URC-CIC Paris Descartes Necker Cochin: collaborator

Study Sites (1)

Rheumatology Department, Cochin Hospital

Paris, IDF, 75014, France

RECRUITING

Biospecimen

Retention: SAMPLES WITHOUT DNA

* Serum samples * Synovial fluid samples

MeSH Terms

Conditions

Arthritis, Juvenile; Cone-Rod Dystrophy 10; Cornea Plana 1

Interventions

Blood Specimen Collection; Arthrocentesis

Condition Hierarchy (Ancestors)

Arthritis; Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Connective Tissue Diseases; Skin and Connective Tissue Diseases; Autoimmune Diseases; Immune System Diseases

Intervention Hierarchy (Ancestors)

Specimen Handling; Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Punctures; Surgical Procedures, Operative; Investigative Techniques; Paracentesis; Therapeutics

Study Officials

• Yannick ALLANORE, PD, PhD

  Cochin Hospital, Assistance Publique des Hôpitaux de Paris (AP-HP)

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Yannick ALLANORE, PD, PhD

CONTACT

0033158412563; yannick.allanore@aphp.fr

Marie BENHAMMANI-GODARD

CONTACT

+33 1 58411190; marie.godard@aphp.fr

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 6, 2022
• First Posted: September 9, 2022
• Study Start: March 13, 2023
• Primary Completion (Estimated): March 1, 2030
• Study Completion (Estimated): March 1, 2030
• Last Updated: September 12, 2025

Record last verified: 2025-09

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)